Sahin Taha Koray, Guven Deniz Can, Ozbay Yakup, Atak Firat, Arslan Sevtap, İcli Mehmet Cihan, Karahan Latif, Kaygusuz Yunus, Arik Zafer, Dizdar Omer, Erman Mustafa, Yalcin Suayib, Onur Mehmet Ruhi, Aksoy Sercan
Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Department of Radiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Immunotherapy. 2025 Jun 27:1-9. doi: 10.1080/1750743X.2025.2525743.
Although immune checkpoint inhibitors (ICIs) have heralded a new era in cancer treatment, many patients do not respond, underscoring the need for biomarkers. The albumin-myosteatosis gauge (AMG) is a recently developed integrated measure of myosteatosis and serum albumin levels, reflecting systemic inflammation and malnutrition. Herein, we investigate the prognostic value of AMG in patients with advanced cancer treated with ICIs.
A total of 308 patients with advanced cancer treated with ICIs were included. Skeletal muscle index and skeletal muscle radiodensity (SMD) were measured from computed tomography images obtained at the level of the L3 vertebra. The AMG was calculated by multiplying SMD by albumin and expressed as an arbitrary unit.
The median age (interquartile range) was 63 (55-70), and 198 (64.3%) were male. Non-small cell lung cancer (NSCLC) was the most common primary cancer (28.2%), followed by RCC (20.8%) and melanoma (20.2%). Multivariable analyses revealed that lower AMG values were independently associated with decreased OS (HR:1.37; 95%CI:1.03-1.82; = 0.032) and PFS (HR:1.39; 95% CI:1.07-1.79; = 0.012) compared to the AMG high-group.
Our findings suggest AMG, an easily accessible novel biomarker, is an independent prognostic factor for survival in patients with advanced cancer treated with ICIs.
尽管免疫检查点抑制剂（ICI）开创了癌症治疗的新时代，但许多患者并无反应，这凸显了生物标志物的必要性。白蛋白-肌少脂变指数（AMG）是一种最近开发的综合测量肌少脂变和血清白蛋白水平的指标，反映全身炎症和营养不良。在此，我们研究AMG在接受ICI治疗的晚期癌症患者中的预后价值。
共纳入308例接受ICI治疗的晚期癌症患者。从L3椎体水平获得的计算机断层扫描图像测量骨骼肌指数和骨骼肌放射密度（SMD）。AMG通过将SMD乘以白蛋白来计算，并以任意单位表示。
中位年龄（四分位间距）为63岁（55-70岁），男性198例（64.3%）。非小细胞肺癌（NSCLC）是最常见的原发癌（28.2%），其次是肾细胞癌（RCC，20.8%）和黑色素瘤（20.2%）。多变量分析显示，与AMG高分组相比，较低的AMG值与总生存期（OS）降低（HR：1.37；95%CI：1.03-1.82；P=0.032）和无进展生存期（PFS）降低（HR：1.39；95%CI：1.07-1.79；P=0.012）独立相关。
我们的研究结果表明，AMG是一种易于获取的新型生物标志物，是接受ICI治疗的晚期癌症患者生存的独立预后因素。
Zotero 插件